Galmed Pharmaceuticals (GLMD) has released an update.
Galmed Pharmaceuticals Ltd. reported a condensed consolidated financial overview for the first quarter ending March 31, 2024, highlighting a net loss of $1,275 thousand, a decrease in total assets from $16,629 thousand to $14,521 thousand, and a slight comprehensive loss. The report also indicates a reduction in both research and development, as well as general and administrative expenses compared to the previous year.
For further insights into GLMD stock, check out TipRanks’ Stock Analysis page.
